Lim Jung-Ah, Lee Soon-Tae, Kim Tae-Joon, Moon Jangsup, Sunwoo Jun-Sang, Byun Jung-Ick, Jung Keun-Hwa, Jung Ki-Young, Chu Kon, Lee Sang Kun
Department of Neurology, Biomedical Research Institute, Seoul National University Hospital, College of Medicine, Seoul National University, Seoul, South Korea.
Department of Neurology, Biomedical Research Institute, Seoul National University Hospital, College of Medicine, Seoul National University, Seoul, South Korea; Department of Neurology, Soonchunhyang University School of Medicine, Seoul, South Korea.
J Neuroimmunol. 2016 Sep 15;298:178-80. doi: 10.1016/j.jneuroim.2016.08.002. Epub 2016 Aug 2.
The aim of this study was to analyze the clinical presentation and provocation factors of rhabdomyolysis in anti-NMDAR encephalitis. Among the 16 patients with anti-NMDAR encephalitis in our institutional cohort, nine patients had elevated CK enzyme levels and clinical evidence of rhabdomyolysis. Rhabdomyolysis was more frequent after immunotherapy. The use of dopamine receptor blocker (DRB) increased the risk of rhabdomyolysis. None of the patients without rhabdomyolysis received DRBs. Rhabdomyolysis is a frequent complication in anti-NMDAR encephalitis and more common after immunotherapy and the use of DRBs increases the risk. Therefore, DRBs should be administered carefully in patients with anti-NMDAR encephalitis.
本研究旨在分析抗N-甲基-D-天冬氨酸受体（NMDAR）脑炎患者横纹肌溶解的临床表现及诱发因素。在我们机构队列中的16例抗NMDAR脑炎患者中，9例患者肌酸激酶（CK）酶水平升高且有横纹肌溶解的临床证据。免疫治疗后横纹肌溶解更为常见。多巴胺受体阻滞剂（DRB）的使用增加了横纹肌溶解的风险。无横纹肌溶解的患者均未接受DRB治疗。横纹肌溶解是抗NMDAR脑炎的常见并发症，在免疫治疗后更为常见，且DRB的使用会增加风险。因此，抗NMDAR脑炎患者应谨慎使用DRB。
